We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab

Garcia J, Zia A. Pediatr Blood Cancer. 2021 May;68(5):e28942.

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies

Nogami K, Soeda T, Matsumoto T, et al. J Thromb Haemost 2018;16:1383–1390.    

Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

Barg AA, Livnat T, Budnik I, et al. [published online ahead of print, 2020 Jul 12]. Br J Haematol. 2020;10.1111/bjh.16964.

Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey

Krumb E, Fijnvandraat K, Makris M, et al. [published online ahead of print Jun 30]. Haemophilia. 2021 Jun 30. doi: 10.1111/hae.14372

Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.

Tripodi A, Chantarangkul V, Novembrino C and Peyvandi F. Clin Chem 2019;65:254–262.

Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile

Abarca-Villaseca V, Soto-Arellano V. Am J Case Rep. 2021 Apr 22;22:e929598

Disruptive technology and hemophilia care: The multiple impacts of emicizumab

Hermans C, Makris M. Res Pract Thromb Haemost. 2021 May 7;5(4):e12508

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A

Knight T, Callaghan MU. Therap Adv Hem. 2018;(Oct), 319–34.

Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays

Kizilocak H, Marquez-Casas E, Malvar J, et al. [published online ahead of print Jun 11]. Haemophilia. 2021 Jun 11. doi: 10.1111/hae.14359

Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A with Factor VIII Inhibitors

Poster Presentation PB0521: Jiménez-Yuste V, Peyvandi F, Klamroth R, et al